多西他赛解救治疗转移性乳腺癌合理剂量的临床研究被引量：2

A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breastcancer

导出

摘要目的评估多西他赛解救治疗转移性乳腺癌的临床疗效和剂量水平的关系。方法回顾性分析200例单药多西他赛解救治疗转移性乳腺癌患者的临床资料，分析其疗效、合理剂量水平和毒副作用。结果200例多西他赛解救治疗转移性乳腺癌患者的客观缓解率（ORR）为27．O％，临床获益率（CBR）为35．0％，无进展生存时间（PFS）为3．8-6．3个月，中位PFS为5．0个月。多西他赛单位体表面积≥90．0mg／㎡组的CBR为50．0％，高于单位体表面积〈90．0mg／㎡组（29．5％，P=0．008）。多西他赛单位体表面积≥90．0mg／㎡组的中位PFS为7．0个月，高于单位体表面积〈90．0mg／㎡组（4．0个月，P=0．045）。多西他赛解救治疗〈75．0mg／㎡组的PFS（7．0个月）高于75．0-84．9mg／㎡组（3．5个月，P=0．018），≥95．0mg／㎡组的PFS（7．0个月）高于75．0-84．9mg／㎡组（3．5个月，P=0．048）。按照解救治疗线数3分层，≤3线解救治疗的转移性乳腺癌患者，多西他赛≥95．0mg／㎡组的PFS（5．0个月）高于75．0-84．9mg／㎡组（3．5个月，P〈0．05）。按照是否接受紫杉类辅助治疗分层，在既往接受紫杉类患者中，多西他赛≥95．0mg／㎡组的PFS（6．0个月）高于75．0-84．9mg／㎡组（3．0个月，P=0．021）。结论多西他赛解救治疗转移性乳腺癌的临床疗效与药物剂量水平有关。 Objective To evaluate the correlation of clinical effects and reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer. Methods We reviewed retrospectively the clinical records of patients with metastatic breast cancer treated with docetaxel and statistically analyzed the correlation between clinical effects and reasonable doses of docetaxel. Results The objective response rate and clinical benefit rate of docetaxol in patients with metastatic breast cancer were 27.0% and 35.0%, respectively, and the median progression free survival （ PFS ） was 5.0 （3.8-6.3） months. In the analysis at a single dose level, the clinical benefit rate and PFS of the ≥90.0 mg/㎡ docetaxel group were superior to that of the 〈 90.0 mg/㎡ group （P = 0.008, P = O. 045 ）. Multi-dose level group stratified analysis showed that the docetaxel 〈75.0 mg/㎡ group was better than the 75.0-84.9 mg/㎡ PFS group （P =0.018）, and the ≥95.0 mg/㎡ group was better than the 75.0-84.9 mg/㎡ group （ P = 0. 048 ）. In patients who received 〉 third line treatment or previously received paelitaxel adjuvant therapy, the PFS of the ≥ 94.9 mg/㎡ docetaxel group was 6.0 months, better than the 3.0 months of the 75.0 - 84.9 mg/㎡ group （ P = 0. 031 ; P = 0.021 ）. Condusiola There is a clear correlation between clinical effects and reasonable doses of docetaxel salvage therapy in patients with metastatic breast cancer.

作者吴世凯马焱孟祥颖孙冰王涛张少华江泽飞宋三泰

机构地区军事医学科学院附属医院乳腺肿瘤内科

出处《中华肿瘤杂志》 CAS CSCD 北大核心 2012年第10期764-769,共6页 Chinese Journal of Oncology

关键词乳腺肿瘤肿瘤转移剂量效应关系药物治疗效果 Breast neoplasms Neoplasm metastasis Dose-response relationship, drug Treatment outcome

分类号 R737.9 [医药卫生—肿瘤]

引文网络
相关文献

参考文献9

1Valero V, Holmes FA, Waiters RS, et ai. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol, 1995, 13:2886-2894.
2Harvey V, Mouridsen H, Semiglazov V, et al. Phase m trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol, 2006, 24:4963-4970.
3Nabhohz JM, Tonkin K, Smylie M, et al. Chemotherapy of breast cancer : are the taxanes going to change the natural history of breast cancer? Expert Opin Pharmacother, 2000, 1:187-206.
4Ravdin PM, Burris HA 3rd, Cook G, et al. Phase ]] trial of doeetaxel in advanced anthmeycline-resistant or anthracenedione- resistant breast cancer. J Clin Oneol, 1995, 13:2879-2885.
5O'Brien ME, Leonard RC, Barrett-Lee PJ, et al. Docetaxel in thecommunity setting: an analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group. Ann Oncol, 1999, 10:205-210.
6Jones SE, Erban J, Overmoyer B, et al. Randomized phase study of docetaxel compared with paelitaxel in metastatic breast cancer. J Clin Oncol, 2005, 23:5542-5551.
7Nabholtz JM, Serm HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomyein plus vinblastine in patients with metastatic breast cancer progressing despite previous anthraeyeline- containing chemotherapy. 304 Study Group. J Clin Oncol, 1999, 17 : 1413-1424.
8Sjstrm J, Blomqvist C, Mouridsen H, et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase Ⅲstudy with crossover on progression by the Scandinavian Breast Group. Eur J Cancer, 1999, 35 : 1194-1201.
9Bonneterre J, Roch6 H, Monnier A, et al. Docetaxel vs 5-fluomuracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer, 2002, 87 : 1210-1215.